| Cat.No. | Name | Information |
|---|---|---|
| M55252 | FS120 | FS120 is a first-in-class dual-agonist tetravalent bispecific antibody targeting CD137 (4-1BB, TNFRSF9) and OX40 (CD134, TNFRSF4). FS120 has the potential to show activity in "cold" tumors and improve outcomes of existing immunotherapies by simultaneously agonizing CD137 and OX40. |
| M55251 | ATOR-1015 | ATOR-1015 is a human CTLA-4 x OX40 targeting IgG1 bispecific antibody with enhanced immune activation and tumor-directed activity for improved efficacy and reduced toxicity. ATOR-1015 induces T-cell activation and Treg depletion in vitro. |
| M55250 | YH002 | YH002 is a recombinant anti-OX40 (CD134, TNFRSF4) humanized IgG1 agonistic antibody. |
| M55249 | HFB 3010 | HFB 3010 (HFB 301001) is a novel second-generation fully human IgG1 class OX40 agonistic monoclonal antibody. |
| M55248 | KN052 | KN052 is a novel recombinant PDL1/OX40 bispecific antibody which can block PDL1 and PD1/CD80 pathway and active the OX40 signal pathway at the same time. |
| M55247 | INBRX-106 | INBRX-106 is a hexavalent, recombinant humanized IgG1, OX40 agonist antibody that targets the human OX40 receptor (TNFRSF4). |
| M55246 | MEDI6469 | MEDI6469 is an activating monoclonal antibody to TNFRSF4 (OX40, CD134), which mimics the binding of the ligand, TNFSF4 (OX40L, CD252), to stimulate proliferation of T-cells and enhance an anti-tumor response. |
| M55245 | GSK3174998 | GSK3174998 is a potent humanized IgG1 agonistic anti-OX40 monoclonal antibody (mAb). In vitro T-cell activation of OX40 with GSK3174998 resulted in enhanced CD4+ and CD8+ effector T-cell proliferation, both in plate-bound as well as soluble PBMC assays. |
| M55241 | INCAGN-1949 | INCAGN-1949 is a novel fully human IgG1 monoclonal anti-OX40 antibody with the potential to enhance tumor-specific T-cell responsiveness, while selectively depleting intratumoral regulatory T cells. Commensurate with its human IgG1 Fc region, INCAGN-1949 can effectively co-engage activating Fcγ receptors on immune effector cells, including natural killer cells and macrophages. |
| M55239 | IMG-007 | IMG-007 is a novel humanized IgG1 mAb that specifically binds to the OX40 receptor and potently blocks the signaling between OX40 and its ligand. IMG-007 has been engineered to have an extended half-life to allow less frequent dosing and a silenced antibody-dependent cell-mediated cytotoxicity (ADCC) function to reduce safety risks. |
| M55238 | BAT6026 | BAT6026 is a novel human anti-OX40 antibody with enhanced antibody dependent cellular cytotoxicity (ADCC) via fucose deletion to strengthen its Treg depletion activity. BAT6026 activated T cells more effectively when clustered by FcγRs engagement and stimulated SEB-pretreated PBMCs to secrete IL-2 cytokines in vitro. |
| M55237 | BGB-A445 | BGB-A445 is a humanized anti-OX40 IgG1 monoclonal agonistic antibody with Fc activity that binds with high specificity and affinity to the extracellular domain of human OX40 and induces an anti-tumor immune response. |
| M55199 | AVTX-009 | AVTX-009 is a humanized monoclonal antibody (IgG4) that binds to interleukin-1β (IL-1β) with high affinity and neutralizes its activity. |
| M55046 | Inetetamab | Inetetamab is a monoclonal antibody binding to domain IV of HER2 receptor. Inetetamab shows antitumor activities when used alone or together with tyrosine kinase inhibitors. |
| M55045 | Izeltabart | Izeltabart is a high-affinity humanized antibody targeting ADAM9. Izeltabart can be used as ADC Antibody for site-specific conjugation with Maytansinoid-based DM21-C to synthesize IMGC936, an Antibody-drug Conjugate with strong anti-cancer activity. IMGC936 exhibits cytotoxicity against ADAM9-positive human tumor cell lines and potent antitumor activity in xenograft tumor models. |
| M55043 | Cinpanemab | Cinpanemab (BIIB054) is a human-derived monoclonal antibody that binds to α-synuclein. Cinpanemab can be used for the research of Parkinson's disease. |
| M55042 | Cofetuzumab | Cofetuzumab (PF-06523435) is a humanized IgG1-κ monoclonal antibody targeting PTK7. |
| M55041 | Crizanlizumab | Crizanlizumab is an anti-P-selectin monoclonal antibody. Crizanlizumab binds to P-selectin and blocks its interaction with P-selectin glycoprotein ligand 1 (PSGL-1). Crizanlizumab prevents vaso-occlusive crises (VOCs). |
| M55035 | Rosnilimab | Rosnilimab is a novel PD-1 checkpoint agonist antibody that reduces overactive T cell inflammation. Rosnilimab optimizes PD-1+ T cell inhibitory signaling by enabling tight immune synapse formation. Rosnilimab restores immune balance bringing T cell composition to a less activated state. |
| M55021 | MK-4830 | MK-4830 is a novel, first-in-class human IgG4 monoclonal antibody targeting the myeloid-specific ILT4 (immunoglobulin-like transcript 4) receptor. MK-4830 catalyzes reprogramming of tumour-associated macrophages, relieving myelosuppression and enhancing T cell function. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
